FibroGen shares take a beating as CEO reveals safety data manipulation for its blockbuster contender roxadustat

FibroGen $FGEN backtracked on some of the key safety data used to boost hopes for their anemia drug roxadustat. And investors quickly crushed its shares in retaliation for the surprise discrepancies.